Luciano Rossetti of Merck Research Laboratories, said: “Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care.”
Incorporated in 1891, Merck is engaged in discovery, development, production and marketing of medicines and vaccines. The company has operations in various countries and Tredaptive is approved in 39 nations, excluding the US.